| Project/Area Number |
24659024
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
FUKUNAGA KOHJI 東北大学, 薬学研究科(研究院), 教授 (90136721)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIODA Norifumi 東北大学, 大学院薬学研究科, 助教 (00374950)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 筋萎縮性側索硬化症 / シグマー１受容体 / ミトコンドリア障害 / 小胞体ストレス / メチルピルビン酸 / ALS治療薬 / 筋萎縮側索硬化症 / sigma-1 受容体 / TDP-43 / TCA 回路 / ピルビン酸 / Sigma-1受容体 / IP3 受容体 / 脳血管性認知症 / 抗うつ薬 |
|---|
| Research Abstract |
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder caused by motor neuron dysfunction. Recently, a E102Q mutation in the chaperone protein sigma-1 receptor (R) was discovered in familial ALS patients. Here, we address mechanisms underlying neurodegeneration caused by this mutation using overexpression analysis in neuro2A cells. Sigma-1R(E102Q) overexpression promoted its dissociation from the endoplasmic reticulum (ER) membrane and its cytoplasmic aggregation, and in turn impaired mitochondrial ATP production. Under ER stress condition, sigma-1R(E102Q) overexpression aggravated mitochondrial damage, thereby causing apoptosis. The enhancement of ATP production by methyl pyruvate treatment rescued mitochondrial damage induced by sigma-1R(E102Q) overexpression. Taken together, phenotypes observed in sigma-1R(E102Q)-overexpressing cells suggest that ATP supplementation by methyl pyruvate is potential therapeutic strategy to treat ALS caused by sigma-1R mutations.
|
